| Ticker: BBII | 375 West Street | |
| Exchange: NASDAQ-National Market | West Bridgewater, Massachusetts 02379 | |
| Industry: Manufacturing | (508) 580-1900 |
| Type of Shares: | Common Shares | Filing Date: | 8/23/96 | |
| U.S. Shares: | 1,600,000 | Offer Date: | 10/31/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $8.00 - $10.00 | |
| Primary Shares: | 1,600,000 | Offer Price: | $8.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.60 | |
| Offering Amount: | $14,400,000 | Selling: | $0.36 | |
| Expenses: | - | Reallowance: | $0.10 | |
| Shares Out After: | - |
| Manager | Tier | Phone |
| Oscar Gruss & Sons Incorporated | Lead Manager | |
| Kaufman Brothers L.P. | Co-manager | (800) 807-8723 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $12.27 | $6.93 | $5.56 | Assets: | $10.05 |
| Net Income: | $0.10 | $0.08 | -$0.04 | Liabilities: | $5.82 |
| EPS: | $0.04 | $0.03 | -$0.01 | Equity: | $4.23 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a leading worldwide provider of proprietary quality control products for use with in vitro diagnostic test kits for the detection, analysis and monitoring of infectious diseases, including AIDS, Hepatitis and Lyme Disease. These products are used to develop test kits, to permit the monitoring of laboratory equipment and personnel, and to help ensure the accurate of test results. The company's products are derived from human plasma and serum using proprietary manufacturing processes. The company believes its Quality Control Panel products are viewed as the current industry standard for the independent assessment of the performance of HIV and Hepatitis test kits. The company also manufactures diagnostic test kit components and provides specialty laboratory services, including clinical trials. To date, the company has sold its products primarily to test kit manufacturers and regulatory agencies, but it has recently begun selling Quality Control Products directly to the emerging end-user market for quality control products for infectious disease test kits. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for repayment of indebtedness, capital expenditures, and general corporate purposes, including working capital and potential acquisitions. |
©1996 IPO Data Systems, Inc. - All rights reserved.